All In Biotech

Drug Trial Radar · NCT05579548

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 22, 2022

Primary completion

Oct 4, 2032

Study completion Oct 4, 2032

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only

Summary

As written by the sponsor on the registry.

This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.

Conditions

  • Phenylketonuria, Maternal

Interventions

  • PegvaliaseDrug

    Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy outcome and infant development for women who have been treated with Palynziq (pegvaliase) within 2 weeks of their last menstrual periodTime frame: 10 years

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Syneos Health

    Wilmington, North Carolina · Recruiting

  • Metabolics and Genetics in Calgary (MAGIC)

    Calgary, Canada · Recruiting

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany · Recruiting

  • Ospedale San Paolo

    Milan, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.